VTRS logo

VTRS
Viatris Inc

3,771
Mkt Cap
$15.51B
Volume
6.54M
52W High
$16.47
52W Low
$7.34
PE Ratio
-4.55
VTRS Fundamentals
Price
$13.47
Prev Close
$13.61
Open
$13.74
50D MA
$14.33
Beta
0.81
Avg. Volume
10.66M
EPS (Annual)
-$3.00
P/B
1.05
Rev/Employee
$476,440.00
$27,822.22
Loading...
Loading...
News
all
press releases
AMRX: 3 Growth Drivers Behind Amneal's 2026 Outlook
Amneal Pharmaceuticals heads into 2026 with diversified growth drivers, rising margins and a faster launch cadence supporting steady revenue expansion.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Is AMRX Stock Undervalued? Sales Multiple, Target, Upside
Amneal Pharmaceuticals trades below peers on sales multiple despite strong gains, with a $14 target hinging on execution, mix shift, and margin strength.
Zacks·1d ago
News Placeholder
Here's How AMRX Is Tapping GLP-1 Demand Through Manufacturing
Amneal Pharmaceuticals taps GLP-1 growth via a Pfizer-linked manufacturing deal, gaining exposure without clinical risks while scaling injectables and peptides.
Zacks·1d ago
News Placeholder
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting Viatris Announces Multiple Data Presentations at the 2026 American Society...
PR Newswire·1d ago
News Placeholder
Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD)
Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for...
PR Newswire·19d ago
News Placeholder
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
Zacks·22d ago
News Placeholder
Viatris Outlines Long-term Financial Targets
(RTTNews) - Viatris (VTRS) said, for combined long-term Targets through 2030, the company expects to deliver 5% to 6% total revenues CAGR, 7% to 8% adjusted EBITDA CAGR, 9% to 10% adjusted EPS CAGR...
Nasdaq News: Markets·23d ago
News Placeholder
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 PR Newswire PITTSBURGH, March...
PR Newswire·23d ago
News Placeholder
Estradiol Hormone Patch Shortage Strains Pharmacies After Warning Lifted
Estradiol Hormone Patch Shortage Strains Pharmacies After Warning Lifted Authored by Jill McLaughlin via The Epoch Times, Some U.S. pharmacies are scrambling to fill estradiol transdermal patch...
Zero Hedge·28d ago
News Placeholder
West Pharmaceutical Services Now #396 Largest Company, Surpassing Viatris
In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, West Pharmaceutical Services, Inc. (Symbol: WST) has taken over the #396 spot from Viatris Inc...
Nasdaq News: Markets·1mo ago
<
1
2
...
>

Latest VTRS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.